论文部分内容阅读
Objective: To retrospectively evaluate the safety and efficacy of radiofiequency ablation (RFA) following transarterial chemoembolization (TACE) for patients with Barcelona Clinic Liver Cancer (BCLC) B, C stages hepatocellular carcinoma (HCC).Methods: Data from all patients who with BCLC B, C stage HCC and underwent RFA following TACE were analyzed.Median progression free survival (PFS), overall survival (OS), and prognostic factors were analyzed with the Kaplan-Meier method and logrank tests.Results: From Feb 2009 to July 2014, a total of 67 patients underwent RFA following TACE for unresectable HCC.The last follow time was ended in november 30,2014, During a median follow-up of 29 months (range 2-55 months), 33 patients died from intrahepatic recurrence and three patients died from non-HCC related causes.The median OS was 38 months (range: 6-55 months) with 1-, 2-,3-and 4-year overall survival rates of 90.7%, 69.7%, 50.7%, and 30.7%respectively.The median Progression free survival was 12 months.Multivariate analysis revealed that age, extrahepatie metastasis, BCLC stage (B or C), lesion count(1,2, 3 or more),tumor diameter and pretreatment serum alpha-fetoprotein level were independent predictors for long-term survival.Conclusion: Combination therapy of TACE with RFA for patients with BCLC B, C stage HCC is safe and effective, which can delay tumor progression and improve the PFS and OS.